New drug combo shows promise for Tough-to-Treat leukemia

NCT ID NCT02756897

First seen Jun 26, 2026 · Last updated Aug 12, 2026 · Updated 5 times

Summary

This phase II trial tests a combination of two targeted drugs, venetoclax and ibrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The study includes patients whose cancer has come back or is hard to treat, as well as some untreated patients with high-risk features. The goal is to see if this drug pair can control the disease better than standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
venetoclax and ibrutinib
What this could lead to
If successful, this combination could offer a more effective way to control CLL without chemotherapy, potentially leading to longer remission.
What could go wrong
This is a phase II trial, so results are still early. There are risks of serious side effects like infections or bleeding, and it may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.